Browse News
Filter News
Found 485,874 articles
-
Maybe timing is everything. On Aug. 28, 2017, Gilead Sciences acquired Kite Pharma for about $11.9B.
-
About 250 Pfizer employees will remain in the Memphis area after the pharma giant secured a partial tax freeze for 14 years from local governments that will save the company an estimated $5.3M in taxes.
-
Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra.
-
Shortly after Rhythm made its public debut on the Nasdaq Exchange, Pfizer has snapped up a small percentage of the company focused on treating rare genetic disorders that lead to obesity.
-
WalletHub recently examined the quarterly filings of hedge funds to determine which stocks they’re buying the most.
-
The company plans to expeditiously advance AMT-061 instead of AMT-060.
-
The initial focus will be on hepatitis b, with an option to expand to additional disease areas.
-
Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug
10/19/2017
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk's diabetes drug semaglutide, a long-acting GLP-1 analogue. -
Tyme’s SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
10/19/2017
The subgroup analysis evaluated three common factors that can influence overall survival in oncology trials.
-
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy
10/19/2017
BioLife Solutions today announced that its customer Kite Pharma has received US FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.
-
Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim)
10/19/2017
Prometic today announced that Health Canada has granted priority review status for the NDS the company plans to file for its plasminogen replacement therapy (RyplazimTM) for the treatment of patients with plasminogen deficiency.
-
MilliporeSigma Brings Customers Closer to Gene Therapy Product Commercialization
10/19/2017
MilliporeSigma today announced that its Carlsbad, CA-based manufacturing facility for the production of BioReliance viral and gene therapy products has completed both a FDA Pre-License inspection and a EMA MAA inspection.
-
Akermes Release: New Study Comparing Effectiveness Of Extended-Release Naltrexone To Buprenorphine-Naloxone For Opioid Dependence Published In JAMA Psychiatry
10/19/2017
Results from the first-ever study directly comparing the effectiveness of once-monthly extended-release naltrexone (VIVITROL) to daily buprenorphine-naloxone in patients with opioid dependence were published this week in the Journal of the American Medical Association (JAMA) Psychiatry.
-
OncoSNIPE Artificial Intelligence Project Officially Launched
10/19/2017
Oncodesign, a biopharmaceutical group specialized in precision medicine, and UNICANCER present the details of the OncoSNIPE project, which aims to develop and apply artificial intelligence techniques to cancer research.
-
BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
10/19/2017
BioMarin updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases.
-
OncoSec Presents Positive Phase II Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
10/19/2017
OncoSec today announced updated Phase 2 clinical and immune monitoring data from patients treated with its investigational therapy, ImmunoPulse IL-12 as a monotherapy versus the combination of ImmunoPulse IL-12 and the approved anti-PD-1 therapy pembrolizumab.
-
NGM Bio Provides Update On NGM282 In NASH
10/19/2017
NGM Bio today provided an update on the development of NGM282, a compound in Phase 2 clinical testing for the treatment of NASH.
-
AOBiome Therapeutics Reports Positive Efficacy Results from Phase IIb Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris
10/19/2017
AOBiome today announced positive efficacy and safety findings from the Phase 2b clinical trial of the Company's Ammonia Oxidizing Bacteria (AOB) product candidate for the treatment of mild-to-moderate acne vulgaris.
-
Corbus Pharmaceuticals Reports Positive Topline Results From Phase 2 Study In Rare Autoimmune Disease Dermatomyositis
10/19/2017
Corbus Pharmaceuticals Holdings announced positive topline results from its 16-week Phase II study of safety and efficacy of anabasum in dermatomyositis (“DM”).
-
Revance Completes Patient Enrollment In Phase 2 Program For RT002 Injectable In The Management Of Plantar Fasciitis
10/19/2017
Revance Therapeutics announced it has completed enrollment of patients in the Company's Phase 2 program investigating the use of DaxibotulinumtoxinA for Injection (RT002) for the management of plantar fasciitis.